Archive

Device for treating challenging bone fractures cleared by FDA

Written by Charlie King | 26 Jul 2023

A new system for fixing bone fractures, called the Bone Bolt System, has been approved for market by the U.S. Food and Drug Administration (FDA), the University of… read more.

FDA approves Bylvay for patients living with cholestatic pruritus due to Alagille syndrome – Ipsen

Written by Charlie King | 24 Jun 2023

Ipsen announced that the FDA has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS). Bylvay is… read more.

FDA approves Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma – Roche

Written by Charlie King | 22 Jun 2023

Roche announced that the FDA has approved Columvi (glofitamab-gxbm) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified… read more.

FDA approval for Inpefa to treat heart failure – Lexicon Pharma

Written by Charlie King | 3 Jun 2023

Lexicon Pharmaceuticals, Inc. announced that the FDA has approved Inpefa (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent… read more.

A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests

Written by Charlie King | 11 May 2023

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly… read more.

1 2 3 Next »

Archive

Device for treating challenging bone fractures cleared by FDA

FDA approves Bylvay for patients living with cholestatic pruritus due to Alagille syndrome – Ipsen

FDA approves Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma – Roche

FDA approval for Inpefa to treat heart failure – Lexicon Pharma

A sharp increase in the price of the gout drug colchicine led to lower use and poorer disease control, UCLA research suggests

Artificial pancreas improves blood sugar control in young children with type 1 diabetes

A drug that treats alcoholism may be the next anti-anxiety medication

Pfizer and BioNTech receive first FDA Emergency Use Authorization of a COVID-19 vaccine booster

FDA accepts REGEN-COV for priority review for treatment and prophylaxis of COVID-19 – Regeneron Pharma

FDA approves Keytruda to treat high-risk early-stage triple-negative breast cancer – Merck Inc.

FDA accepts Alymsys filing for metastatic colorectal cancer – Amneal Pharma

FDA grants accelerated approval for Aduhelm to treat Alzheimer’s disease – Biogen + Eisai

Archive

Subscribe for our mailing list

Follow Us